US HCPs: Get ready for a big week at #VEITH2025 in New York City! Join our expert faculty for podium presentations and interactive sessions featuring new data and cutting-edge innovation. #STORMPE #RCT #CAVT #RubyXL

US HCPs: #STORMPE #RCT now published in @CircAHA! Backed by peer-reviewed level 1 evidence for the treatment of acute intermediate high-risk PE, #CAVT shows superior efficacy over AC alone. https://t.co/bOZnj21TaK Rx only. Risk: https://t.co/SILdiRZoH4 Clinical results may vary

#STORM-PE CAVT+ AC > AC alone: 1. greater reduction in RV strain 2. Greater improvement in pulm perfusion 3. Faster stabilization of vital signs 4. Faster return to baseline functional status 5. Improved walking distance Time to offer this tx for all Intermediate-High Risk pts?

Live @TCTConference @crfheart amazing session today discussing the impact of the #STORM-PE data on the future of #PE care. Thank you @PenVascular for the support of the study.

RT @t_intheleadcoat: Yesterday was a monumental day for PE pts & for the space with the FIRST ever RCT comparing mechanical thrombectomy #C…

Live @TCTConference First podium presentation of the #STORM-PE trial!! First RCT of thrombectomy vs Anticoag ever!! Thank you to @crfheart @PenVascular @PERTConsortium for advancing the field

Mechanical Thrombectomy Outshines Anticoagulation Alone in STORM-PE https://t.co/w2zv5y35qF

Dr. Suhail Dohad shares outcomes from the STRIKE-PE study 🫁. With the first 600 enrolled patients treated using the Indigo Aspiration Thrombectomy System, results highlight a low rate of adverse events, improved functional outcomes, and improved QOL at the 1-year mark.#PERT2025

US HCPs: #LightningFlash 2.0 is setting the standard for PE treatment. Join Drs. @vivianbishay and @kavaliIR for a #PERT2025 trainee bootcamp session on the benefits of #CAVT.

Join us at #PERT2025 as Drs. @t_intheleadcoat, @RosovskyRachel, @DrMahirElder, and @JonnyMoriarty discuss advancing comprehensive PE care with #CAVT – putting the patient first.

Join us THIS WEEK at #NYEVS2025!🫀📝 Featuring: 🔴Aortic and Peripheral Arterial Disease topics 🟢Live case transmissions 🔵Hands-on demonstrations with the latest techniques, equipment, and technology ⚡️Register NOW! https://t.co/yWKzCgB7Nj #cardiology

US HCPs: Lightning Bolt 6X with TraX is now available in 150 cm, designed to help manage below-the-knee thrombus and maintain the power of CAVT. #BOLTMode #CAVTforBTK Read more here: https://t.co/IAw1eq5wMy Rx only. Risk info: https://t.co/SILdiRZoH4 Clinical results may vary

US HCPs: NOW introducing Lightning Bolt 6X with TraX in 150 cm length. Read more on the newest addition to your complete CAVT platform for the management of arterial thrombus: https://t.co/IAw1eq5wMy #CAVTforBTK Rx only. Risk: https://t.co/SILdiRZoH4 Clinical results may vary

🗣️ From innovation to impact. Join our Lunch Symposium on Sept 5th at #EVS2025 to hear physician perspectives on #CAVT and #Ruby coils. Drs. @DanHan, @TomMaldonadoMD, Khanjan Nagarsheth, and @KathleenOzsvath

Live @MountSinaiIR Honored to present the Primary Outcomes for #STORM-PE #tct2025. First RCT of Mechanical Thrombectomy plus Anticoag vs Anticoag alone for #PE @crfheart @TCTMD CRF unveils late-breaking clinical trials for TCT 2025 in San Francisco

#NYEVS2025 is just 2 weeks away! Join us September 11-13 for 3 different educational tracts 📅 🩺Non-Aortic PAD 🫀Aortic 👣Podiatry View all Agendas & Register here: https://t.co/yWKzCgBFCR #cardiology #interventionalcardiology #peripheralarterialdisease #endovascular #aortic

Penumbra’s inaugural Physician Leaders Program brought together multi-disciplinary doctors for a day of connection, CAVT innovation, and leadership. Read more here: https://t.co/YD1gwGcicQ #PhysicianLeaders #HealthcareInnovation

The 2025 New York Endovascular Summit (NYEVS) is a multidisciplinary conference focused on the diagnosis and treatment of peripheral arterial disease (PAD). This two-day conference, taking place from September 12-13, 2025, will feature different tracks: Non-Aortic PAD, Aortic,

.@penumbrainc has announced the completion of enrolment in the STORM-PE clinical trial https://t.co/aVy4KyItY7

US HCPs: 🏥 CAVT patients were up to 75% more likely to be discharged home vs. embolectomy #THRIVEStudy. Learn more about the real-world applications of #CAVT: https://t.co/J6skuzk83A #ALI #VAM25 Rx only. Risk: https://t.co/SILdiRZoH4 Clinical results may vary.